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In a time of uncertainties such the present days, we all
look for guiding principles. When no guidelines are avail-
able, principles shape our actions. Above all, do no harm
has been ours as we are facing the largely unknown chal-
lenge of the global COVID-19 epidemic. This mentality
guided our efforts to strike the balance between reducing
exposure of patients and health care providers to risk of
infection on the one hand, and on the other, meeting our
daily goal of providing optimal oncologic treatment in a
tertiary center of national relevance.
We acted in an ever-changing context. Starting on
February 21st, the first non-imported Covid-19 positive
cases were recorded across Northern Italy. Between
February 25th and March 4th, three different urgent de-
crees of the Italian Prime Minister progressively locked
down the entire peninsula in an effort to contain the
spread of the novel coronavirus SARS-CoV-2. In a matter
of a few hours, our patients’ ability to reach our center
was impaired due to logistical reasons. Public transporta-
tion was drastically reduced; those who had been in a
high-incidence area such as our Institute’s region were re-
quired to enter a 2-week self-quarantine upon return to
their homes.
While general hospitals across our region struggled to
organize the response, which naturally focused on con-
verting near-all activities to assist COVID-19 patients,
our Institute’s mission to treat oncologic patients was
preserved through measures implemented over a course
of 2 weeks. A surveillance department within our center
was created in order to screen oncologic patients with
symptoms of infection and to contain already admitted
subjects who developed the disease. Screening at the In-
stitute’s entrance was put in place, restricting caregivers’
access to selected cases and blocking all subjects with
body temperature above 37,5 °C (99,5 °F), proposing
them COVID-19 tests. Hand sanitizer and personal pro-
tective equipment (PPE) such as surgical masks were
also distributed at the entrance. Social distancing was
ensured in the waiting rooms by restricting sitting areas.
Our unit, which is fully dedicated to medical treatment
of head and neck cancer (HNC) patients (see Table 1 for
activity details), adopted some additional preventive
measures beginning February 24th. We report here
about the organizational impact of all implemented mea-
sures on a special cancer population.
All patients with scheduled in- or out-patient visits were
contacted the day prior to the visit to assess for fever, flu-
like symptoms, and recent travel history – especially inter-
national travel, as well as for exposure to know COVID-19
cases in the previous 3 weeks. Patients with flu-like symp-
toms were referred to the emergency service for proper
screening, while subjects with high exposure risk (e.g.:
residing in high incidence areas) were rescheduled. Further-
more, to minimize the risk of exposure, long-term follow-
up visits for patients treated with curative intent (ie, those
patients on observation for over 2 yrs) were generally
rescheduled. Subjects on watchful waiting, such as those
with slowly evolving differentiated thyroid carcinomas or
salivary gland cancers, were asked to send in already per-
formed radiologic exams, skipping the clinical evaluation
while still providing a feedback on disease evolution. Oral
treatments such as tyrosine kinase inhibitors (TKI) and
androgen-deprivation therapy (ADT) were delivered to pa-
tients’ homes, provided they executed and shared with their
clinician routine tests and did not report any new toxicity.
We guaranteed treatment continuity to subjects with
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curable disease and all of those with ongoing intravenous
therapies.
Symptomatic patients with rapidly evolving onco-
logical disease and those near the end of life represented
a challenge. Whenever possible, referral to home services
for symptomatic relief was undertaken. Working in co-
ordination with the regional emergency service, septic/
acute patients were directed to the most appropriate
center – either a COVID-19-dedicated hospital in highly
suspect cases, or to our Institute when tumor-related
conditions were deemed more probable.
Of note, some patients autonomously rescheduled
their appointments out of fear of being exposed to the
new coronavirus while accessing to our Institute.
Maintenance of staff health throughout this epidemic
is of paramount importance. Given the high COVID-19
incidence in our area, each subject should be considered
a potential case. Therefore, adequate PPE were employed
while visiting outpatients and frequent cleaning of offices
and medical devices was implemented. While few
COVID-19 cases were detected in our institutes’ patient
population, a rising number of health care providers
were exposed. Therefore, whenever possible remote
work was adopted to reduce the diffusion risk among
employees.
We are aware that the pandemic side-effects will be
perceived much longer than the outbreak itself. There-
fore, since February 24th we have tracked the dynamic
of rescheduled patients in relationship with national
COVID-19 case growth and the ever more stringent
lockdown policies (Fig. 1a). Data in Fig. 1b shows the
steep increase in rescheduled visits after travel restric-
tion policies took place, with visit activity reduced in half
in the second and third weeks of March. We differenti-
ated the reasons for visit rescheduling between clinical
Table 1 Summary of 2018 Activity of the Head and Neck
Cancer Medical Oncology Unit at Milan National Cancer Institute
Activity Number
Number of admitted HNC pts 485
Number of IV systemic therapies to inpatients 374
curative 285
palliative 89
Number of outpatients visits 2582
Number of IV systemic therapies to outpatients 675
curative 107
palliative 568
Curative chemo-radiotherapy for HNC 67
Post-Operative chemo-radiotherapy for HNC 19
Fig. 1 Dynamic of rescheduled patients (pts) at the Head and Neck Cancer Medical Oncology Unit at Milan National Cancer Institute in
relationship with national COVID-19 cases growth and the ever more stringent lockdown policies. a Total confirmed positive Covid-19 cases in
Italy; b Proportion of cancelled (red) and performed (blue) visits; c Characteristics of the rescheduled subjects according to treatment intent
(curative in red vs palliative in blue) and d reason for visit cancellation (logistic causes related to Covid-19 in red, other clinical reason in blue). In
the abscissa we signaled in red the date of urgent decrees of the Italian Prime Minister which progressively locked down the country
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causes (i.e.: neutropenia) and COVID-19-related causes
(i.e.: flight cancellation, subject residing in red-zone
areas). COVID-19-related causes represented the major-
ity of rescheduling causes (Fig. 1d). A large proportion
of rescheduled visits clustered on Tuesdays and Fridays
when multidisciplinary follow-up of potentially cured
patients takes place (Fig. 1c). These data reflect the diffi-
culties in being true to the do no harm principle: sparing
useless exposure to cured patients is as crucial as inter-
cepting a potentially curable HNC recurrence. Careful
case-by-case evaluation should be recommended while
selecting the right candidate to skip possibly life-saving
controls.
We also want to appreciate the proportion of HNC pa-
tients directly affected by COVID-19 infection. Therefore,
we recently started an observational study investigating
our units’ population on active treatment with access to
our department from February 2020 up to the end of
March; HNC patients on follow-up with access in the last
6months will also be investigated. We will collect via tele-
phone information regarding development of flu-like
symptoms, province of residence in the last two months
and exposure to known COVID-19 cases. Clinical data on
disease characteristics and oncologic treatment will be col-
lected and correlated to the investigations’ results.
Whenever uncertainties need to be faced, real-time
data collection and information-sharing are pivotal in
order to collectively design guidelines. Hopefully, our
efforts can provide a meaningful piece in the mosaic of
the health care response to this evolving pandemic.
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